伊立替康联合奥沙利铂治疗可降低晚期结直肠癌的近期不良反应发生率

Combined Treatment of Irinotecan and Oxaliplatin could Reduce the Short-Term Incidence of Adverse Reactions in Patients with Advanced Colorectal Cancer

观察伊立替康联合奥沙利铂在治疗晚期结直肠癌中的近期不良反应发生率。收集2009年4月至2015年10月在我院住院接受治疗的晚期结肠癌患者42例。随机分成两组,每组21例,观察组为伊立替康联合奥沙利铂,对照组为奥沙利铂联合亚叶酸钙、5-氟尿嘧啶。主要观察指标为治疗效果及近期不良反应事件。结果显示,伊立替康联合奥沙利铂在治疗晚期结直肠癌的总体疗效上与对照组无统计学差异;近期总体不良反应发生率23.8%,显著低于对照组总体不良反应发生率57.1%,其中以消化系统和血液系统不良反应为主。伊立替康联合奥沙利铂治疗晚期结直肠癌的近期总体不良反应发生率相对较低,在临床上应用过程中需要注意消化系统和血液系统相关的不良反应的发生。

The aim of this study was to observe the incidence of short-term adverse reactions of irinotecan combined with oxaliplatin in the treatment of advanced colorectal cancer. 42 patients with advanced colorectal cancer treated in our hospital from April 2009 to October 2015 were collected and randomly divided into two groups, with 21 cases in each group. Experimental group was treated with irinotecan combined oxaliplatin, and control group was treated with oxaliplatin combined with leucovorin and 5-fluorouracil. The main outcome measures were therapeutic effect and adverse events. The results showed that there was no statistical difference of the objective response rate（ORR）between the experimental group and the control group. The short-term incidence of adverse reactions in the observation group was 23.8%, which was significantly lower than that of the control group（57.1%）. The incidence of adverse reactions were mainly in the digestive system and hematological system. The incidence of adverse reactions of irinotecan combined with oxaliplatin in the treatment of advanced colorectal cancer was relatively low, and the adverse reactions of digestive system and blood system should be taken into account in the clinical application.